Patents by Inventor Trine Skovlund Ryge

Trine Skovlund Ryge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
    Patent number: 10406207
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes related diseases or disorders.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: September 10, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Trine Skovlund Ryge Neerup, Torben Østerlund, Jakob Lind Tolborg, Keld Fosgerau, Ulrika Martensson, Marianne Brorson, Kamilla Rolsted
  • GLP-1 receptor agonist peptide gastrin conjugates
    Patent number: 9861706
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: January 9, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Jakob Lind Tolborg, Trine Skovlund Ryge Neerup, Keld Fosgerau, Torben Østerlund, Dorthe Lennert Christensen Almholt, Lone Frost Larsen
  • PEPTIDE CONJUGATES OF GLP-1 RECEPTOR AGONISTS AND GASTRIN AND THEIR USE
    Publication number: 20170281709
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes related diseases or disorders.
    Type: Application
    Filed: December 16, 2016
    Publication date: October 5, 2017
    Inventors: Trine Skovlund Ryge NEERUP, Torben ØSTERLUND, Jakob Lind TOLBORG, Keld FOSGERAU, Ulrika MARTENSSON, Marianne BRORSON, Kamilla ROLSTED
  • Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
    Patent number: 9649362
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: May 16, 2017
    Assignee: Zealand Pharma A/S
    Inventors: Trine Skovlund Ryge Neerup, Torben Østerlund, Jakob Lind Tolborg, Keld Fosgerau, Ulrika Martensson, Marianne Brorson, Kamilla Rolsted
  • PEPTIDE CONJUGATES OF GLP-1 RECEPTOR AGONISTS AND GASTRIN AND THEIR USE
    Publication number: 20160184400
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Application
    Filed: June 10, 2015
    Publication date: June 30, 2016
    Inventors: Trine Skovlund Ryge Neerup, Torben Østerlund, Jakob Lind Tolborg, Keld Fosgerau, Ulrika Martensson, Marianne Brorson, Kamilla Rolsted
  • GLP-1 RECEPTOR AGONIST PEPTIDE GASTRIN CONJUGATES
    Publication number: 20160082118
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Application
    Filed: September 24, 2015
    Publication date: March 24, 2016
    Inventors: Jakob Lind TOLBORG, Trine Skovlund Ryge NEERUP, Keld FOSGERAU, Torben ØSTERLUND, Dorthe Lennert Christensen ALMHOLT, Lone Frost LARSEN
  • GLP-1 receptor agonist peptide gastrin conjugates
    Patent number: 9259477
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: February 16, 2016
    Assignee: Zealand Pharma A/S
    Inventors: Jakob Lind Tolborg, Trine Skovlund Ryge Neerup, Keld Fosgerau, Torben Østerlund, Dorthe Lennert Christensen Almholt, Lone Frost Larsen
  • Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
    Patent number: 9089538
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: July 28, 2015
    Assignee: Zealand Pharma A/S
    Inventors: Trine Skovlund Ryge Neerup, Torben Østerlund, Jakob Lind Tolborg, Keld Fosgerau, Ulrika Mårtensson, Marianne Brorson, Kamilla Rolsted
  • Glucagon analogues
    Patent number: 8680049
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: December 15, 2008
    Date of Patent: March 25, 2014
    Assignee: Zealand Pharma A/S
    Inventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard, Trine Skovlund Ryge Neerup
  • Glucagon analogues
    Patent number: 8642541
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: December 15, 2008
    Date of Patent: February 4, 2014
    Assignee: Zealand Pharma A/S
    Inventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard, Trine Skovlund Ryge Neerup
  • PEPTIDE CONJUGATES OF GLP-1 RECEPTOR AGONISTS AND GASTRIN AND THEIR USE
    Publication number: 20130143793
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Application
    Filed: April 27, 2011
    Publication date: June 6, 2013
    Applicant: ZEALAND PHARMA A/S
    Inventors: Trine Skovlund Ryge Neerup, Torben Østerlund, Jakob Lind Tolborg, Keld Fosgerau, Ulrika Mårtensson, Marianne Brorson, Kamilla Rolsted
  • GLUCAGON ANALOGUES
    Publication number: 20110293587
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: December 15, 2008
    Publication date: December 1, 2011
    Applicant: Zealand Pharma A/S
    Inventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard, Trine Skovlund Ryge Neerup
  • GLUCAGON ANALOGUES
    Publication number: 20110286981
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: December 15, 2008
    Publication date: November 24, 2011
    Applicant: Zealand Pharma A/S
    Inventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard, Trine Skovlund Ryge Neerup
  • Glucagon analogues
    Patent number: 7994122
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain in a subject. In particular, the invention provides novel glucagon analogue peptides effective in such methods and in the treatment of obesity, eating disorders, metabolic syndrome, and non-alcoholic liver steatosis. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: August 9, 2011
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Eddi Meier, Trine Skovlund Ryge, Jens Rosengren Daugaard
  • GLUCAGON ANALOGUES
    Publication number: 20100204105
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain in a subject. In particular, the invention provides novel glucagon analogue peptides effective in such methods and in the treatment of obesity, eating disorders, metabolic syndrome, and non-alcoholic liver steatosis. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: June 16, 2008
    Publication date: August 12, 2010
    Applicant: Zealand Pharma A/S
    Inventors: Ditte Riber, Eddi Meier, Trine Skovlund Ryge, Jens Rosengren Daugaard
  • TRUNCATED PTH PEPTIDES WITH A CYCLIC CONFORMATION
    Publication number: 20100048462
    Abstract: The present invention provides PTH peptides which are cyclised substitution analogues of the truncated PTH fragment PTH (1-17) and which preferably retain the desired or similar biological activity of human PTH (1-34).
    Type: Application
    Filed: December 6, 2007
    Publication date: February 25, 2010
    Applicant: Zealand Pharma A/S
    Inventors: Trine Skovlund Ryge, Martin Stahlhut, Carsten Boye Knudsen, Bjarne Due Larsen